Press releases

2017-04-04 – Press release

Paul Sekhri joins Topas Therapeutics as Chairman of the Board

2016-03-22 – Press release

Evotec spins off auto-immune disease company as ‘Topas Therapeutics GmbH’

Topas Therapeutics GmbH is based on a proprietary nanoparticle platform which supports antigen-specific tolerance induction for multiple indications
Strong consortium consisting of Epidarex Capital, EMBL Ventures, Gimv and Evotec AG supports strategic Series A financing round of EUR 14 m
Initiation of first clinical trials expected in 2017

2016-03-22 – Press release

Topas Therapeutics Raises EUR 14 Million to Treat Immunological Disorders

Causal therapies based on novel approach for antigen-specific tolerance induction
Significant opportunities through near term clinical proof-of-concept (“POC”)
Strong strategic syndicate includes Epidarex Capital, EMBL Ventures, Gimv, and Evotec AG